September 28,2007
Sen. Grassley urges FDA to implement recommendations of Inspector General for human subjects in clinical trials
WASHINGTON — Sen. Chuck Grassley is calling on the Food and Drug Administration to implement recommendations stemming from an independent review of the agency’s oversight of clinical trials involving human subjects.
“We’re all in debt to the individuals who volunteer for the clinical trials that advance medicine and lead to lifesaving cures. The Food and Drug Administration needs to make sure these human subjects are treated properly and fully informed,” Grassley said.
Grassley made his appeal in a letter to the FDA Commissioner. The text is below. The report of the Inspector General for the Department of Health and Human Services containing the recommendations is posted at http://finance.senate.gov, along with this news release.
###
Next Article Previous Article
Recent News
- Wyden Statement on Supreme Court Ruling to Restrict Emergency Room Care for Women
- Wyden Statement on HHS Watchdog Report on Lack of Oversight at Youth Residential Treatment Facilities
- Wyden Calls for Action to Stop PBM Middlemen from Flagrantly Flouting Medicare Rules that Protect Pharmacies
- Wyden Statement on Final Rules Promoting Good-Paying Clean Energy Jobs in America
- Wyden Statement at Finance Committee Hearing on Work and Social Security